Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Intellia Thera CS (NQ: NTLA ) 15.14 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Intellia Thera CS < Previous 1 2 ... 8 9 10 11 12 13 14 15 Next > 12 Health Care Stocks Moving In Wednesday's After-Market Session January 05, 2022 Gainers SomaLogic (NASDAQ:SLGC) shares mo... Via Benzinga Top 5 Moonshots for 2022 Countdown: My No. 5 Pick December 22, 2021 2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year. Via InvestorPlace 36 Stocks Moving In Tuesday's Mid-Day Session December 07, 2021 Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares climbed 123.2% to $6.16. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and accessories.... Via Benzinga Intellia Therapeutics & UiPath Elliott Wave Analysis October 09, 2021 US Stocks NTLA &PATH technical analysis, Elliott Wave forecast & trading. Via Talk Markets Stock Trading: Intellia Therapeutics Inc & Zillow Technical Analysis October 02, 2021 Intellia and Zillow technical analysis, Elliott Wave forecast. Via Talk Markets Where Intellia Therapeutics Stands With Analysts September 24, 2021 Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed t... Via Benzinga 54 Biggest Movers From Yesterday December 08, 2021 Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 66.7% to close at $4.60 on Tuesday. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and... Via Benzinga Do CRISPR Therapeutics and Intellia Face a Big Safety Risk? November 21, 2021 CRISPR gene editing is promising, but there's a risk that it can cause unwanted mutations. Via The Motley Fool Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar? November 18, 2021 Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation... Via Benzinga Technical Analysis : Pinduoduo (PINS) & Intellia Therapeutics (NTLA) September 01, 2021 Here's a technical analysis of two stocks: Pinduoduo (PDD) & Intellia Therapeutics. Via Talk Markets CareDx & Intellia Therapeutics Elliott Wave Analysis August 25, 2021 At this point the flat correction into wave (4) could be completed, if not we are just missing one last leg down. Via Talk Markets Looking for Growth in Small and Mid Cap Life Science Stocks November 15, 2021 2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps. Via Talk Markets Intellia Therapeutics, Inc (NTLA) Q3 2021 Earnings Call Transcript November 06, 2021 NTLA earnings call for the period ending October 3, 2021. Via The Motley Fool Topics Earnings Exposures Financial The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO November 04, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... Via Benzinga Exposures COVID-19 The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline October 31, 2021 Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... Via Benzinga EVP And Chief Medical Officer Of Intellia Therapeutics Trades $340K In Company Stock October 18, 2021 David Lebwohl, EVP And Chief Medical Officer at Intellia Therapeutics (NASDAQ:NTLA), made a large buy and sell of company shares on October 14, according to a new SEC filing. What... Via Benzinga Topics Regulatory Compliance Exposures Legal Regulatory 2 Gene-Editing Stocks to Have on Your Radar Right Now October 17, 2021 They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies. Via The Motley Fool Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week October 15, 2021 A key gene-editing readout had Cathie Wood shuffling her portfolio. Via The Motley Fool Exposures Product Safety The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal October 13, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the... Via Benzinga Exposures Product Safety 12 Health Care Stocks Moving In Friday's Intraday Session October 08, 2021 Gainers ChemoCentryx (NASDAQ:CCXI) stock increased by 70.43% to $33.41 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 74.6... Via Benzinga Intellia To Test Second CRISPR Therapeutic In Hereditary Angioedema Patients October 06, 2021 The New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) has signed off Intellia Therapeutics Inc's (NASDAQ: NTLA) Phase 1/2 study of NTLA-2002... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2021 October 05, 2021 Upgrades Wolfe Research upgraded the previous rating for PACCAR Inc (NASDAQ: Via Benzinga The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs October 08, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... Via Benzinga Exposures Product Safety Benzinga's Top Ratings Upgrades, Downgrades For September 24, 2021 September 24, 2021 Upgrades Berenberg upgraded the previous rating for Tenable Holdings Inc (NASDAQ: Via Benzinga Intellia To Test CRISPR-Engineered TCR-T Cell Candidate In Acute Myeloid Leukemia Patients September 16, 2021 The FDA has signed off Intellia Therapeutics Inc's (NASDAQ: NTLA) investigational new drug (IND) application for NTLA-5001. Related Content: Intellia... Via Benzinga Exposures Product Safety 12 Health Care Stocks Moving In Thursday's Pre-Market Session September 16, 2021 Gainers Leap Therapeutics (NASDAQ:LPTX) stock rose 32.64% to $2.56 during Thursday's pre-market session. The company's market cap stands at $152.7 million. Phio... Via Benzinga Forget About the Genomic Revolution, the Proteomic Revolution Is Coming September 03, 2021 Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. Via InvestorPlace Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today August 23, 2021 Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology. Via InvestorPlace US Stocks: AME, AVAV, NIO, NTLA, PDD & SNAP Technical Analysis August 09, 2021 Technical stocks analysis: Ametek, AeroVironment, Nio Inc, Intellia Therapeutics, Pinduoduo, and Snap. Via Talk Markets Intellia Therapeutics, inc (NTLA) Q2 2021 Earnings Call Transcript August 06, 2021 NTLA earnings call for the period ending June 30, 2021. Via The Motley Fool Topics Earnings Exposures Financial < Previous 1 2 ... 8 9 10 11 12 13 14 15 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
